PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 8-K

What Happened

• Pacific Biosciences of California, Inc. announced that Michele Farmer voluntarily resigned as Chief Accounting Officer effective March 21, 2026, to pursue another opportunity; her departure is not related to any known disagreement with the company and she will not receive severance. Chief Financial Officer Jim R. Gibson (CFO since 2025) will serve as the company’s principal accounting officer effective upon Farmer’s resignation; no change to his compensation was made.
• On March 5, 2026 the company entered a binding term sheet with Personal Genomics of Taiwan, Inc. (PGI) that provides Pacific Biosciences a worldwide, royalty-free, non-exclusive license under U.S. Patent No. 7,767,441 (and related family) and a five-and-a-half-year covenant not to sue. The term sheet resolves existing litigation between the parties and includes a fixed payment schedule from Pacific Biosciences to PGI.

Key Details

• CAO resignation: Michele Farmer effective March 21, 2026; no severance; no disagreement reported. Jim R. Gibson to be principal accounting officer; no compensation change.
• Patent/license: worldwide, royalty-free, non-exclusive license under U.S. Patent No. 7,767,441 (and family); 5.5-year covenant not to sue that runs with the patents and binds successors/transferees.
• Payment schedule: $8,000,000 in Q1 2026, then $5,000,000 in Q1 of each 2027, 2028 and 2029. The 2027 payment increases by $1,000,000 if 2026 revenue ≥ $165,000,000 and by another $1,000,000 if 2026 revenue ≥ $180,000,000 (so 2027 could be up to $7,000,000).
• Settlement effects: dismissal of claims and counterclaims between the parties and a release of pre-covenant damages claims.

Why It Matters

• The settlement converts potential litigation exposure into defined, time-bound payments and a limited license/covenant not to sue, reducing legal uncertainty for Pacific Biosciences’ long‑read commercial ecosystem. That may provide operational certainty for product commercialization and partner/customer relationships.
• The agreement creates near-term cash obligations (base payments totaling $23M across 2026–2029, with potential to reach $25M if revenue triggers are met) that investors should consider when assessing cash flow and capital planning.
• Management continuity: the CFO will assume the principal accounting officer role immediately upon the CAO’s departure and the filing states no compensation changes or special arrangements tied to that appointment. The company also includes standard forward-looking caution language about risks and uncertainties.